JP2025501307A5 - - Google Patents
Info
- Publication number
- JP2025501307A5 JP2025501307A5 JP2024539913A JP2024539913A JP2025501307A5 JP 2025501307 A5 JP2025501307 A5 JP 2025501307A5 JP 2024539913 A JP2024539913 A JP 2024539913A JP 2024539913 A JP2024539913 A JP 2024539913A JP 2025501307 A5 JP2025501307 A5 JP 2025501307A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- cancer
- bispecific molecule
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163295681P | 2021-12-31 | 2021-12-31 | |
| US63/295,681 | 2021-12-31 | ||
| PCT/US2022/082628 WO2023130073A2 (en) | 2021-12-31 | 2022-12-30 | Bispecific molecules to target the first cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501307A JP2025501307A (ja) | 2025-01-17 |
| JP2025501307A5 true JP2025501307A5 (cg-RX-API-DMAC7.html) | 2026-01-13 |
Family
ID=87000357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024539913A Pending JP2025501307A (ja) | 2021-12-31 | 2022-12-30 | 最初の細胞を標的とする二重特異性分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250051475A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4456918A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025501307A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118510539A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022426854A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023130073A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025085511A1 (en) * | 2023-10-18 | 2025-04-24 | University Of Washington | Systems and methods for polymer-mediated activation of engineered cells |
| WO2025264955A1 (en) * | 2024-06-21 | 2025-12-26 | Tfc Therapeutics, Inc. | Multispecific proteins and related methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3876002B2 (ja) * | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| WO2010117448A2 (en) * | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| US20150094224A1 (en) * | 2010-05-04 | 2015-04-02 | Paul Walfish | Methods for the diagnosis or prognosis of breast cancer |
| WO2012122228A2 (en) * | 2011-03-07 | 2012-09-13 | Temple University - Of The Commonwealth System Of Higher Education | Biomarkers of chronic obstructive pulmonary disease |
| JP2015515264A (ja) * | 2012-03-12 | 2015-05-28 | スカラテック メディカル アーベー | 疾患の処置のためのキメラタンパク質 |
| CN112513081A (zh) * | 2018-06-14 | 2021-03-16 | 生物蛋白有限公司 | 多重特异性抗体构建体 |
| CA3110837A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| WO2020056162A1 (en) * | 2018-09-12 | 2020-03-19 | Oregon Health & Science University | Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival |
| US11634501B2 (en) * | 2019-07-19 | 2023-04-25 | Oncoresponse, Inc. | Immunomodulatory antibodies and methods of use thereof |
-
2022
- 2022-12-30 AU AU2022426854A patent/AU2022426854A1/en active Pending
- 2022-12-30 WO PCT/US2022/082628 patent/WO2023130073A2/en not_active Ceased
- 2022-12-30 US US18/719,725 patent/US20250051475A1/en active Pending
- 2022-12-30 JP JP2024539913A patent/JP2025501307A/ja active Pending
- 2022-12-30 CN CN202280087171.5A patent/CN118510539A/zh active Pending
- 2022-12-30 EP EP22917606.0A patent/EP4456918A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth | |
| Guo et al. | Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment | |
| JP2022515318A5 (cg-RX-API-DMAC7.html) | ||
| JP2009505676A5 (cg-RX-API-DMAC7.html) | ||
| JP2010535713A5 (cg-RX-API-DMAC7.html) | ||
| JP2013502913A5 (cg-RX-API-DMAC7.html) | ||
| JP2016503295A5 (cg-RX-API-DMAC7.html) | ||
| JP2021502810A5 (cg-RX-API-DMAC7.html) | ||
| JP2021510736A5 (cg-RX-API-DMAC7.html) | ||
| JP2019533475A5 (cg-RX-API-DMAC7.html) | ||
| JP2021511811A5 (cg-RX-API-DMAC7.html) | ||
| JP2021528047A5 (cg-RX-API-DMAC7.html) | ||
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2020522474A5 (cg-RX-API-DMAC7.html) | ||
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| JP2011505146A5 (cg-RX-API-DMAC7.html) | ||
| JP2015529641A5 (cg-RX-API-DMAC7.html) | ||
| JP2017521054A5 (cg-RX-API-DMAC7.html) | ||
| JP2024504471A5 (cg-RX-API-DMAC7.html) | ||
| JP2008508858A5 (cg-RX-API-DMAC7.html) | ||
| Wang et al. | NKG2D immunoligand rG7S-MICA enhances NK cell-mediated immunosurveillance in colorectal carcinoma | |
| JP2019512210A5 (cg-RX-API-DMAC7.html) | ||
| Abushukair et al. | Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance | |
| Hong et al. | The role of cancer‐associated fibroblasts in the tumour microenvironment of urinary System |